Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT05849220 Not yet recruiting - NAFLD Cirrhosis Clinical Trials

Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.

Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function parameters. It is also known that cirrhotic patients are at a higher risk of developing CKD at 1 year when compared to non cirrhotics. With this study we aim to study the role Dapagliflozin in cirrhotic patients in reducing the development of CKD, its impact on cirrhotic cardiomyopathy and its role in improvement of metabolic profile and liver related outcomes.

NCT ID: NCT05835648 Not yet recruiting - Clinical trials for Chronic Kidney Disease

Effect of Dietary Fiber on Non-dialysis Patients With Chronic Kidney Disease

Start date: April 30, 2023
Phase: N/A
Study type: Interventional

The main objective of this study was to investigate the effect of dietary fiber on anemia and glomerular filtration rate in non-dialysis patients with chronic kidney disease. Participants will be randomly divided into a dietary fiber intervention group and a blank control group. The patients in the dietary fiber intervention group will have dietary fiber intake survey conducted by dietitians on the basis of basic treatment. Supplemented dietary fiber was given on the basis of daily diet, once a day, 1 piece each time, before meals, and the intervention lasted for 3 months. The blank control group was followed up without intervention. Clinical data, blood, urine and stool samples were collected at the initial diagnosis and at each follow-up site.

NCT ID: NCT05835089 Not yet recruiting - Clinical trials for Evaluation of Some Puberty-related Hormones Among Children and Adolescents With Chronic Kidney Diseases

Evaluation of Some Puberty-related Hormones Among Children and Adolescents With Chronic Kidney Diseases

Start date: May 2023
Phase:
Study type: Observational

Puberty is the process of transition from childhood into adolescence, signaling the readiness of the human body for reproduction. The Hypothalamic-Pituitary Gonadotropin axis plays the primary role in initiating the puberty, where the hypothalamus secrets gonadotropin releasing hormone (GnRH) in a pulsatile manner, which in turn stimulates the release of luteinizing hormone (LH), and follicle stimulating hormone (FSH) from the anterior lobe of the pituitary gland, and in a final step these hormones stimulate the gonads to release their sex hormones (Testosterone and Estradiol) . Chronic illnesses can affect this physiological process resulting in delayed puberty . Delayed puberty is defined as the lack of pubertal signs until the age of 13 years in girls, and the age of 14 years in boys. Delayed puberty is classified into two categories according to their cause; central gonadotropin deficiency (hypogonadotropic hypogonadism) and this type comprises delayed puberty due to chronic illness, while the second category of delayed puberty is due to gonadal disorders (hypergonadotropic hypogonadism). Delayed puberty is common among pediatric patients with chronic kidney disease (CKD) - where glomerular filtration rate (GFR) is less than 60 ml/min per 1.73 m2. Previous studies suggested that, the cyclic pattern of GnRH release is lost in patients with CKD resulting in impairment of gonadotropins secretion from the anterior pituitary gland. Multiple hormonal factors had been proposed to be responsible for the pubertal delay in patients with CKD, the most prominent of which is the increasing levels of prolactin, LH and GnRH (4). Prolactin normally inhibits the release of GnRH from hypothalamus thus inhibiting the initiation of puberty and it was found to increase in patients with CKD secondary to increased production, slightly decreased clearance and decreased responsiveness to the hypothalamic inhibition of prolactin secretion. Furthermore, recent studies reported that the Kisspeptin protein play an important role in the regulation and control of normal puberty, As it was found that the Kisspeptin neurons (the rostral periventricular region of the third ventricle (RP3V) and arcuate nucleus (ARC), are found in close association with the GnRH releasing neurons in the hypothalamus suggesting that these neurons might play a crucial role in activating and restoring the pulsatile release of GnRH, It was also found that inactivating mutations of the gene encoding for kisspeptin were associated with hypogonadotropic hypogonadism.

NCT ID: NCT05819320 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Mucocutaneous Manifestations in Patients With Chronic Kidney Disease inNewVally and Assuit;Hospital Based Study

Start date: June 2024
Phase:
Study type: Observational [Patient Registry]

1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients in Eldakhla General Hospital, New Valley and in Assiut University hospital . 2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Eldakhla general hospital in New Vally and pediatric and adult renal units of Assuit university hospital .

NCT ID: NCT05793346 Not yet recruiting - Pregnancy Related Clinical Trials

Pregnancy-associated Progression of Chronic Kidney Disease: A Study Protocol for the Development and Validation of a Clinical Predictive Tool

PREDICT
Start date: March 2023
Phase:
Study type: Observational

To develop and validate a tool that estimates the degree of pregnancy-associated progression of renal disease in women with CKD and pregnancy outcomes in an international multicentre cohort study.

NCT ID: NCT05774392 Not yet recruiting - Clinical trials for End Stage Kidney Disease

An Observational Study of Patients With Chronic Kidney Disease

Start date: May 2023
Phase:
Study type: Observational

TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).

NCT ID: NCT05734989 Not yet recruiting - Type 2 Diabetes Clinical Trials

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

Start date: April 2024
Phase:
Study type: Observational

In this study, the investigators will utilize community organizations to screen Hispanics/Latino(a)s for kidney disease, diabetes, and other risk factors, and refer them for care with a PCP. Additionally, the investigators will implement an intervention in local health clinics to assist PCPs with screening and treating patients with diabetes. Completion of the project will hopefully slow progression of kidney disease among Hispanic/Latino(a) patients in Durham, and the information gained will allow the investigators to eventually perform the intervention on a larger scale.

NCT ID: NCT05714176 Not yet recruiting - Clinical trials for CKD - Chronic Kidney Disease

Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children

Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

This is a randomized, parallel study that will be conducted on pediatric patients with CKD.

NCT ID: NCT05696028 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Comparison of Different Gfr Measurements in Chronic Kidney Diseases

Start date: February 1, 2023
Phase:
Study type: Observational

Comparison of different Gfr measurements in Chronic Kidney Diseases

NCT ID: NCT05691257 Not yet recruiting - Heart Failure Clinical Trials

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to conduct a a cohort study to evaluate the efficacy and safety of the efficacy and safety of roxadustat for the treatment of anemia, quality of life and cardiac function in patients with heart failure and chronic kidney disease.